Kancera AB (Publ), a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally.
+ 2 more risks
Imperfect balance sheet with weak fundamentals.
Share Price & News
How has Kancera's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KNCQ.F has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how KNCQ.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how KNCQ.F performed against the US Market.
Price Volatility Vs. Market
How volatile is Kancera's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Kancera undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate KNCQ.F's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate KNCQ.F's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: KNCQ.F is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: KNCQ.F is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KNCQ.F's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KNCQ.F is overvalued based on its PB Ratio (7.7x) compared to the US Biotechs industry average (3.2x).
How is Kancera forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kancera has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of KNCQ.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Kancera's filings and announcements here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Kancera performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KNCQ.F is currently unprofitable.
Growing Profit Margin: KNCQ.F is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: KNCQ.F is unprofitable, and losses have increased over the past 5 years at a rate of -28% per year.
Accelerating Growth: Unable to compare KNCQ.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KNCQ.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).
Return on Equity
High ROE: KNCQ.F has a negative Return on Equity (-226.56%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Kancera's financial position?
Financial Position Analysis
Short Term Liabilities: KNCQ.F's short term assets (SEK12.6M) exceed its short term liabilities (SEK8.5M).
Long Term Liabilities: KNCQ.F's short term assets (SEK12.6M) exceed its long term liabilities (SEK8.5M).
Debt to Equity History and Analysis
Debt Level: KNCQ.F's debt to equity ratio (44.4%) is considered high.
Reducing Debt: KNCQ.F's debt to equity ratio has increased from 9.8% to 44.4% over the past 5 years.
Inventory Level: KNCQ.F has a high level of physical assets or inventory.
Debt Coverage by Assets: KNCQ.F's debt is covered by short term assets (assets are 1.5x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KNCQ.F has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: KNCQ.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of -26.7% each year
What is Kancera's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate KNCQ.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate KNCQ.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KNCQ.F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KNCQ.F's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KNCQ.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Thomas Olin (61yo)
Mr. Thomas Olin, Ph.D. serves as the Chief Executive Officer of Kancera AB. Mr. Olin serves as Senior Director of Business Development at Biovitrum. He founded small biotech start-up. He has been Chief Exe ...
CEO Compensation Analysis
Compensation vs Market: Thomas's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD519.76K).
Compensation vs Earnings: Thomas's compensation has been consistent with company performance over the past year.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.6%.
Kancera AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Kancera AB (publ)
- Ticker: KNCQ.F
- Exchange: OTCPK
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr150.668m
- Listing Market Cap: kr15.561m
- Shares outstanding: 199.83m
- Website: https://www.kancera.com
- Kancera AB (publ)
- Karolinska Institutet Science Park
- Banvaktsvägen 22
- Stockholm County
- 171 48
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|KAN||OM (OMX Nordic Exchange Stockholm)||Yes||Common Shares||SE||SEK||Feb 2011|
|3EE||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Feb 2011|
|KNCQ.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Feb 2011|
Kancera AB (Publ), a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. Its drug development projects include ROR inhibitors for the treatment of leukemia and solid tumors; PFKFB inhibitors for reducing cancer’s energy supply and inhibiting DNA repair; HDAC6, an enzyme that controls the functions of the cell skeleton; and AZD8797 Fractalkine inhibitors that stop tumor growth and relieve severe pain. The company was founded in 2010 and is based in Solna, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/10/28 00:39|
|End of Day Share Price||2019/07/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.